Tempus AI Raises $460 Million with Zero‑Coupon Convertible Notes

Deal Overview Tempus AI, a Nevada‑incorporated AI‑focused biotech, signed an Indenture on May 12, 2026 with U.S. Bank Trust Company, National Association as trustee. The agreement authorizes the issuance of 0.00% convertible senior notes in aggregate principal up to $460 million. The notes are zero‑coupon, accruing no periodic interest, and will mature on June 15, 2032.

Conversion Mechanics Holders may convert the notes into Tempus AI’s Class A common stock under the conversion privileges set out in Article 14 of the Indenture. Conversion rates are tied to a fixed formula that adjusts for stock splits, recapitalizations, or other corporate actions, ensuring parity with the market price at conversion. The conversion feature provides investors with upside potential while preserving the company’s cash flow.

Redemption and Repurchase Rights Tempus AI can redeem the notes early under Article 16, subject to notice periods and payment of a make‑whole amount. Conversely, if a “fundamental change” such as a merger or asset sale occurs, noteholders may compel the company to repurchase the notes at par, per Article 15. These provisions protect both the issuer and investors from adverse corporate events.

Covenants and Default Provisions The indenture imposes standard affirmative and negative covenants—including maintenance of office and agency, delivery of periodic compliance certificates, and adherence to Rule 144A reporting. Events of default trigger acceleration of the principal and the imposition of a special interest rate, with the trustee empowered to enforce remedies on behalf of noteholders.

Strategic Rationale By tapping a zero‑interest, convertible structure, Tempus AI secures a substantial, non‑dilutive capital infusion while limiting cash outlays. Management cites the proceeds as earmarked for research and development, strategic acquisitions, and expanding its AI‑driven platform. The conversion option also aligns investor interests with the company’s growth trajectory, potentially converting debt into equity as the stock appreciates.

Regulatory and Closing Conditions The issuance is subject to customary securities law filings, board resolutions, and delivery of execution certificates to the trustee. The governing law is New York, with jurisdiction provisions outlined in Article 17.

Market Reaction Tempus AI’s shares were trading at $46.95, down 3.12% on the day of the filing, reflecting broader market weakness (S&P 500 down 0.15%). The stock’s RSI of 32 and its position near the low end of its 52‑week range suggest continued pressure, though the financing could bolster confidence in the company’s long‑term growth plan.

Overall, the $460 million convertible note program provides Tempus AI with a flexible financing tool that balances immediate capital needs with future equity upside, a move that could prove pivotal as the company scales its AI‑enabled biotech offerings.